New antibody combo for COVID-19 passes early safety check
NCT ID NCT05181683
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested whether a combination of two antibodies (casirivimab and imdevimab) is safe and tolerable in healthy adults. Forty-five volunteers received the antibodies either as a shot under the skin or through an IV. The main goal was to check for side effects, not to treat or prevent COVID-19. The study is complete and helps guide future research.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC STABLE ILLNESS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Regeneron Study Site
Miami, Florida, 33186, United States
-
Regeneron StudySite
Winter Park, Florida, 32789, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug change future treatments? early safety trial begins
- Can brain scans unlock the secret to hearing in crowded rooms?
- Can a Light-Guided device make arterial sticks easier?
- Water workouts could be the key to back pain relief
- Could everyday disinfectants be harming us? a new study investigates
- Can a new drug keep the Heart's beat steady? trial puts verducatib to the test